Patents Examined by Marcia S. Noble
  • Patent number: 10583180
    Abstract: The present invention relates to the prevention and/or treatment of ADA-SCID, in a patient.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: March 10, 2020
    Assignees: UCL Business LTD, The Regents of the University of California
    Inventors: Adrian Thrasher, Donald Kohn, Bobby Gaspar
  • Patent number: 10584314
    Abstract: An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells. The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 10, 2020
    Assignees: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT, SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki Azuma, Taku Tanaka, Tadashi Yokoi
  • Patent number: 10577630
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 3, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Le Cong, Fei Ran
  • Patent number: 10563210
    Abstract: The present invention relates to a method for producing an interleukin-2 protein using methylotrophic yeast. The method for producing interleukin-2 according to the present invention shows high cell growth and protein synthesis rates by use of the established optimal cell line, and produces a large amount of a protein comprising interleukin-2 by use of the established optimal culture conditions utilizing methanol that is an inexpensive carbon source. In addition, the method according to the present invention isolates and purifies the protein by a simple process. Accordingly, the method according to the present invention highly pure interleukin-2, and thus has a significant effect on the mass-production of interleukin-2.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: February 18, 2020
    Assignee: SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
    Inventors: Sang-Ki Rhee, Eun O Park, Hoon Seo, Guang Jin Choi, Keon-Hyoung Song
  • Patent number: 10563176
    Abstract: An in vitro human cardiac multi potent or unipotent cell that has the ability to proliferate; may be maintained in standard cardiac stem cell media; can differentiate to a progenitor, precursor, or somatic cell; has the characteristics of a cardiac stem cell, a cardiac precursor cell, or a cardiac progenitor cell; does not exhibit uncontrolled growth, teratoma formation, or tumor formation in vivo; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a cardiac stem cell, a cardiac precursor cell, or a cardiac progenitor cell; and is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; wherein the cell comprises at least one transiently expressed polypeptide or an expression vector.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 18, 2020
    Assignee: Genesis Technologies Limited
    Inventors: Jan-Eric Ahlfors, Rouwayda El-Ayoubi
  • Patent number: 10561687
    Abstract: Provided are methods for producing compositions comprising a population of cardiomyocytes enriched for or substantially devoid of sinoatrial node-like pacemaker cardiomyocytes (SANLCM) from human pluripotent stem cells (hPSCs), and methods of use thereof.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: February 18, 2020
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Gordon Keller, Stephanie Protze
  • Patent number: 10557123
    Abstract: A method of obtaining a neural multipotent, unipotent or somatic cell, including: i) providing a cell of a first type which is not a neural multipotent, unipotent or somatic cell; ii) increasing expression of at least one neural multipotent or unipotent gene regulator in the cell of a first type, to a level at which the at least one neural multipotent or unipotent gene regulator is capable of driving transformation of the cell of a first type into the neural multipotent, unipotent or somatic cell, wherein the at least one multipotent or unipotent gene regulator is Musashi1 (Msi1), Neurogenin 2 (Ngn2), or both Msi1 and Ngn2; and iii) placing or maintaining the cell in a neural cell culture medium and maintaining sufficient intracellular levels of the at least one multipotent or unipotent gene regulator for a sufficient period of time to allow a stable neural multipotent, unipotent or somatic cell to be obtained.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: February 11, 2020
    Assignee: Genesis Technologies Limited
    Inventors: Jan-Eric Ahlfors, Rouwayda El-Ayoubi
  • Patent number: 10555904
    Abstract: The present invention relates to a pouch-like structure useful for mechanically preventing distension and/or resisting dilation of the heart and for supporting the hearts function by controllable and paracrine support of a failing heart in a mammal. The pouch-like structure is composed at least partly of engineered tissue comprising genetically engineered cells, such as genetically engineered cells other than cardiac myocytes whereby said genetically engineered cells contain a gene encoding a paracrine factor, said gene encoding the paracrine factor being under control of an inducible promoter system or a heterologous promoter system. Further, the present invention relates to a method for the preparation of the pouch-like structure for therapeutic, disease modelling, and drug development applications. In addition, the present invention relates to cells other than cardiac myocytes for use in the preparation of the pouch-like structure as described herein.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: February 11, 2020
    Assignee: Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaesmedizin
    Inventors: Wolfram Hubertus Zimmermann, PohLoong Soong
  • Patent number: 10548926
    Abstract: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: February 4, 2020
    Assignee: CELULARITY, INC.
    Inventor: Naoko Takebe
  • Patent number: 10543070
    Abstract: The invention relates to methods of increasing genetic merit of swine by establishing a plurality of mating subtypes for a line of swine, and determining a percentage of progeny that are male for each of the mating subtypes, or a percentage of progeny that are female for each of the mating subtypes, that would result, relative to a control, in an increase in genetic merit in the line; the invention further relates to sorting a sperm cell sample from a male swine in one of the mating subtypes into one or more subpopulations of sperm cells, wherein a majority of sperm cells in a subpopulation of sperm cells bear X chromosomes or Y chromosomes, and inseminating one or more female swine in the one of the mating subtypes with the subpopulation of sperm cells to achieve the percentage of progeny that are male, or the percentage of progeny that are female, determined to increase genetic merit relative to the control.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: January 28, 2020
    Assignee: Inguran, LLC
    Inventors: Hein van der Steen, Gregg Bevier
  • Patent number: 10542734
    Abstract: The invention relates to methods of increasing the genetic progress of a line, breed or herd of swine through the use of sex-selected sperm cells in artificial insemination techniques. The invention also encompasses methods of artificially inseminating a swine via deep intrauterine catheter or via a laparoscopic procedure, which allow the use of reduced doses of sex-selected sperm cells.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: January 28, 2020
    Assignee: Inguran, LLC
    Inventors: Juan Moreno, Gregg Bevier, John Dobrinsky
  • Patent number: 10533157
    Abstract: Cancer immunotherapy using genetically engineered NK cells is enhanced by expression of recombinant co-stimulatory molecules to deliver co-stimulatory signals to a recipient host's immune cells to enhance an immune response.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: January 14, 2020
    Assignees: NANTBIO, INC., NANT HOLDINGS IP, LLC
    Inventors: Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh
  • Patent number: 10532112
    Abstract: An object of the present invention is to provide a method for producing a non-human primate model of AMD, a method for evaluating the efficacy of a test substance in the prevention or treatment of AMD using the AMD animal model produced according to this method, and a method for screening substances effective in the prevention or treatment of AMD using the aforementioned AMD animal model. The method for preparing the AMD animal model consists of administering sodium iodate into a vitreous body of a non-human primate, and the method for evaluating the efficacy of a test substance in the prevention or treatment of AMD consists of preparing a non-human primate model of AMD according to the aforementioned method for preparing an AMD animal model, and evaluating the efficacy of the test substance in the prevention or treatment of AMD using the resulting AMD animal model.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 14, 2020
    Assignees: Hamamatsu Pharma Research, Inc.
    Inventor: Hiroyuki Takamatsu
  • Patent number: 10501725
    Abstract: The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: December 10, 2019
    Assignee: KEIO UNIVERSITY
    Inventors: Shigeto Shimmura, Shin Hatou, Kazuo Tsubota
  • Patent number: 10471157
    Abstract: Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: November 12, 2019
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Patent number: 10472611
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: November 12, 2019
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10457917
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: October 29, 2019
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Patent number: 10457911
    Abstract: Culture media which contain a water-soluble polymer, such as polyvinyl alcohol and the like, and albumin, and the like, are useful for the proliferation of stem cells, and show good culture results, particularly with iPS cells, and maintain the stability of the medium properties, as well as using a reduced amount of albumin.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: October 29, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventors: Yoko Kuriyama, Satoru Okamoto, Manabu Kitazawa, Nao Sugimoto, Takuya Matsumoto
  • Patent number: 10443045
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: October 15, 2019
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10441609
    Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: October 15, 2019
    Assignee: Miromatrix Medical Inc.
    Inventors: Harald Ott, Doris Taylor